Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication

Target: CHRNA7 Composite Score: 0.669 Price: $0.70▲34.2% Citation Quality: Pending neurodegeneration Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🟢 Parkinson's Disease 🔥 Neuroinflammation 🔴 Alzheimer's Disease 🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration

🏆 ChallengeGut Microbial Metabolites as Early Causal Drivers of Alzheimer's Patho$1.8M bounty →

✓ All Quality Gates Passed

Quality Report Card click to collapse

Composite: 0.669

Top 31% of 1374 hypotheses

T1 Established

Multi-source converged and validated

T0 Axiom requires manual override only

B Mech. Plausibility 15% 0.60 Top 58%

C+ Evidence Strength 15% 0.50 Top 66%

A Novelty 12% 0.80 Top 25%

B+ Feasibility 12% 0.70 Top 31%

B+ Impact 12% 0.70 Top 42%

B Druggability 10% 0.60 Top 44%

A Safety Profile 8% 0.80 Top 17%

B+ Competition 6% 0.70 Top 39%

B Data Availability 5% 0.60 Top 50%

B Reproducibility 5% 0.60 Top 46%

Evidence

12 supporting | 4 opposing

Citation quality: 100%

Debates

1 session A+

Avg quality: 0.95

Convergence

1.00 A+ 30 related hypothesis share this target

From Analysis:

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?

→ View full analysis & debate transcript

Hypotheses from Same Analysis (8)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration

Score: 0.888 | Target: NLRP3, CASP1, IL1B, PYCARD

Microglial AIM2 Inflammasome as the Primary Driver of TDP-43 Proteinopathy Neuroinflammation in ALS/FTD

Score: 0.824 | Target: AIM2, CASP1, IL1B, PYCARD, TARDBP

Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-Synuclein Aggregates Drives Non-Cell-Autonomous Neurodegeneration

Score: 0.822 | Target: NLRP3, CASP1, IL1B, PYCARD

Mitochondrial DAMPs-Driven AIM2 Inflammasome Activation in Neurodegeneration

Score: 0.805 | Target: AIM2, CASP1, IL1B, PYCARD

Calcium-Dysregulated mPTP Opening as an Alternative mtDNA Release Mechanism for AIM2 Inflammasome Activation in Neurodegeneration

Score: 0.804 | Target: AIM2, CASP1, IL1B, PYCARD, PPIF

Mitochondrial DNA-Driven AIM2 Inflammasome Activation in Neurodegeneration

Score: 0.803 | Target: AIM2, CASP1, IL1B, PYCARD

Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflammatory Priming

Score: 0.789 | Target: TLR4

Targeted Butyrate Supplementation for Microglial Phenotype Modulation

Score: 0.700 | Target: GPR109A

→ View full analysis & all 9 hypotheses

Description

Mechanistic Overview

...

Mechanistic Overview

Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication starts from the claim that modulating CHRNA7 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Gut dysbiosis disrupts vagal cholinergic anti-inflammatory pathways by reducing acetylcholine-producing bacteria and damaging enteric neurons. Vagus nerve stimulation combined with choline supplementation could restore this protective pathway and reduce systemic inflammation driving Parkinson's disease progression. ## The Cholinergic Anti-Inflammatory Pathway: A Gut-Brain Immune Circuit The vagus nerve serves as the primary bidirectional communication highway between the gut and the brain, carrying both afferent (gut-to-brain) sensory signals and efferent (brain-to-gut) motor and autonomic commands. The cholinergic anti-inflammatory pathway (CAP) is a critical neural circuit in which efferent vagal signals suppress peripheral inflammation through acetylcholine (ACh) release. This pathway was first characterized by Kevin Tracey and colleagues, who demonstrated that electrical stimulation of the vagus nerve could dramatically reduce systemic TNF-alpha levels during endotoxemia — an effect mediated entirely by acetylcholine acting on alpha-7 nicotinic acetylcholine receptors (α7nAChR) expressed on macrophages and other immune cells. The circuit operates as follows: inflammatory signals from the gut (cytokines, pathogen-associated molecular patterns) activate vagal afferent neurons in the nodose ganglion, which relay to the nucleus tractus solitarius (NTS) in the brainstem. The NTS projects to the dorsal motor nucleus of the vagus (DMV), which sends efferent cholinergic signals back to the gut via the vagus nerve. In the gut, these efferent fibers synapse on enteric neurons in the myenteric and submucosal plexuses, which in turn release acetylcholine that activates α7nAChR on resident macrophages, dendritic cells, and innate lymphoid cells. Activation of α7nAChR triggers the JAK2-STAT3 signaling cascade in these immune cells, which suppresses NF-kB-dependent transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, HMGB1) while preserving anti-inflammatory cytokine production (IL-10). ## Gut Dysbiosis and Cholinergic Pathway Disruption in Neurodegeneration Multiple lines of evidence connect gut dysbiosis to impaired vagal cholinergic signaling in Parkinson's disease and Alzheimer's disease: Reduced acetylcholine-producing bacteria: The gut microbiome includes several bacterial species capable of synthesizing acetylcholine via choline acetyltransferase homologs, including Lactobacillus plantarum, Bacillus subtilis, and certain Clostridium species. Metagenomic analyses of PD patient stool samples consistently show reduced abundance of these species, with a corresponding decrease in fecal acetylcholine levels. This microbial ACh contributes to local mucosal immune regulation and amplifies the vagal cholinergic signal — its loss creates a deficit that cannot be fully compensated by neuronal ACh alone. Enteric neuron damage: Alpha-synuclein aggregates, the pathological hallmark of PD, are found in enteric neurons of the gut plexuses years to decades before they appear in the brain. The "Braak hypothesis" proposes that PD pathology originates in the gut and propagates to the brain via the vagus nerve. These enteric alpha-synuclein aggregates impair enteric neuron function, reducing both the ACh output of cholinergic enteric neurons and the relay capacity of the enteric nervous system. Damaged enteric neurons also release inflammatory mediators that further disrupt mucosal barrier integrity. Vagal tone reduction: PD patients show reduced heart rate variability (HRV), a clinical measure of vagal tone, even in prodromal stages. Reduced vagal tone means reduced efferent cholinergic signaling to the gut, weakening the anti-inflammatory reflex. This creates a feed-forward cycle: gut inflammation damages enteric neurons, which impairs vagal signaling, which reduces cholinergic anti-inflammatory tone, which permits more inflammation. Intestinal barrier disruption: Gut dysbiosis in PD is associated with increased intestinal permeability ("leaky gut"), allowing bacterial endotoxins (lipopolysaccharide, LPS) and inflammatory mediators to enter the systemic circulation. Chronic low-grade endotoxemia activates systemic and central immune responses, with LPS crossing the blood-brain barrier and directly activating microglial TLR4 receptors, promoting neuroinflammation in substantia nigra and other vulnerable brain regions. ## The α7nAChR Node: Where Vagal Signaling Meets Immune Regulation The alpha-7 nicotinic acetylcholine receptor (α7nAChR, encoded by CHRNA7) is the critical effector of the cholinergic anti-inflammatory pathway. On macrophages and microglia, α7nAChR activation: 1. Inhibits the NLRP3 inflammasome: ACh binding to α7nAChR activates the Nrf2 antioxidant pathway and inhibits mitochondrial ROS production, preventing the assembly of the NLRP3 inflammasome complex and reducing IL-1β and IL-18 processing and secretion. 2. Suppresses NF-kB translocation: α7nAChR signaling through JAK2-STAT3 induces expression of SOCS3 (Suppressor of Cytokine Signaling 3), which inhibits NF-kB nuclear translocation and thus reduces transcription of TNF-α, IL-6, and other pro-inflammatory genes. 3. Promotes phagocytic clearance: In microglia, α7nAChR activation enhances phagocytosis of amyloid-beta and alpha-synuclein aggregates while maintaining an anti-inflammatory phenotype — effectively promoting "silent" phagocytosis without the cytokine storm that accompanies FcR-mediated or complement-mediated uptake. 4. Supports BBB integrity: α7nAChR on brain endothelial cells maintains tight junction integrity and reduces BBB permeability. Cholinergic deficiency increases BBB leakage, allowing peripheral immune cells and inflammatory mediators to infiltrate the brain parenchyma. ## Therapeutic Strategy: Dual Vagal-Nutritional Intervention The proposed intervention combines vagus nerve stimulation (VNS) with targeted choline supplementation to restore the cholinergic anti-inflammatory pathway from both ends: ### Vagus Nerve Stimulation (VNS) Non-invasive transcutaneous VNS (tVNS) devices stimulate the auricular branch of the vagus nerve through the ear, activating the same brainstem nuclei as surgical VNS without requiring implantation. tVNS has shown anti-inflammatory effects in clinical studies: - Reduces plasma TNF-α, IL-6, and CRP in healthy volunteers and patients with rheumatoid arthritis - Increases heart rate variability, reflecting enhanced vagal tone - Reduces microglial activation markers in neuroimaging studies (TSPO-PET) - Currently in Phase 2 trials for PD (NCT04381936) and AD (NCT04908358) The key advantage of tVNS is that it bypasses the damaged enteric neurons, directly activating the central vagal circuit. This is important because in PD, the enteric nervous system is already compromised by alpha-synuclein pathology — stimulating the vagus centrally can restore efferent cholinergic output even when afferent relay from the gut is impaired. ### Choline Supplementation Choline is the essential precursor for acetylcholine synthesis. Citicoline (CDP-choline) and alpha-GPC (alpha-glycerophosphocholine) are bioavailable choline sources that cross the blood-brain barrier and increase both central and peripheral ACh levels: - Citicoline: Has neuroprotective properties beyond cholinergic support, including membrane stabilization and dopamine synthesis enhancement. Meta-analyses show cognitive benefits in vascular dementia and post-stroke patients. It also serves as a precursor for phosphatidylcholine synthesis, supporting neuronal membrane repair. - Alpha-GPC: More rapidly increases plasma and brain ACh levels than other choline sources. Phase 3 trials in AD (Gliatilin) showed benefits in cognitive endpoints, though methodological quality was limited. The combined approach addresses a critical limitation of each monotherapy: VNS alone increases vagal firing but may be limited by insufficient ACh substrate availability, while choline supplementation alone cannot overcome the impaired vagal relay in patients with enteric neuron damage. ### Probiotic Adjunct: Restoring Microbial ACh Production The intervention could be further enhanced by probiotic supplementation with acetylcholine-producing bacterial strains. Lactobacillus plantarum PS128, which has shown anti-inflammatory and neuroprotective effects in PD mouse models, produces ACh and also modulates serotonin and dopamine metabolism. Clinical trials of PS128 in PD patients have shown improvements in motor symptoms and quality of life. ## Preclinical Evidence Vagotomy studies: Truncal vagotomy in rodents abolishes the cholinergic anti-inflammatory reflex, leading to exaggerated gut inflammation and accelerated alpha-synuclein propagation to the brain. Conversely, epidemiological studies have shown that patients who underwent truncal vagotomy have a 40-50% reduced risk of PD — seemingly paradoxical, but explained by the interruption of retrograde alpha-synuclein transport from gut to brain. VNS in PD models: In rotenone and 6-OHDA PD models, chronic VNS reduces dopaminergic neuron loss in substantia nigra by 30-50%, decreases microglial activation, and improves motor performance. The neuroprotective effect is abolished by α7nAChR antagonists (mecamylamine), confirming that it operates through the cholinergic anti-inflammatory pathway. Germ-free mouse studies: Germ-free mice show reduced enteric and central cholinergic tone, with decreased ACh levels in both the gut and brain. Colonization with ACh-producing bacteria (L. plantarum) restores cholinergic signaling and reduces neuroinflammation in response to LPS challenge. ## Evidence For This Hypothesis - Vagus nerve stimulation reduces neuroinflammation and protects dopaminergic neurons in PD mouse models (Farrand et al., Brain Stimulation 2017) - PD patients show reduced vagal tone (HRV) even in prodromal stages (Postuma et al., Brain 2012) - α7nAChR agonists suppress microglial activation and protect against neurodegeneration in vitro and in vivo (Shytle et al., J Neuroinflammation 2004) - Gut dysbiosis in PD includes reduced ACh-producing bacteria (Sampson et al., Cell 2016) - Truncal vagotomy epidemiological data supports gut-brain vagal involvement in PD (Svensson et al., Ann Neurol 2015) - tVNS clinical trials in PD and AD show anti-inflammatory biomarker responses (Badran et al., Brain Stimulation 2022) ## Evidence Against This Hypothesis - The vagotomy-PD risk reduction is inconsistent across epidemiological cohorts, with some studies finding no effect (Tysnes et al., Ann Neurol 2015) - tVNS effects on neuroinflammation may be transient and require continuous or chronic stimulation to be clinically meaningful - Choline supplementation alone has not shown consistent cognitive benefits in large-scale AD/PD trials - The "Braak hypothesis" of gut-origin PD pathology remains debated; not all PD patients show prodromal GI symptoms - Restoring cholinergic signaling may be insufficient if enteric neuron damage from alpha-synuclein is irreversible" Framed more explicitly, the hypothesis centers CHRNA7 within the broader disease setting of neurodegeneration. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating CHRNA7 or the surrounding pathway space around Vagal cholinergic anti-inflammatory pathway (α7nAChR) can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.50, novelty 0.80, feasibility 0.70, impact 0.70, mechanistic plausibility 0.60, and clinical relevance 0.33.

Molecular and Cellular Rationale

The nominated target genes are `CHRNA7` and the pathway label is `Vagal cholinergic anti-inflammatory pathway (α7nAChR)`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: CHRNA7 (α7nAChR) expression is reduced in substantia nigra microglia and enteric neurons in PD post-mortem tissue. Vagal motor neurons in the dorsal motor nucleus show alpha-synuclein pathology and reduced choline acetyltransferase (ChAT) expression in early PD stages, consistent with impaired cholinergic output. This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of CHRNA7 or Vagal cholinergic anti-inflammatory pathway (α7nAChR) is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Identifies CHRNA7 nodes as potential signals in cognitive decline, suggesting cholinergic pathway involvement. Identifier 41663888. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Demonstrates nicotinic acetylcholine receptors can modulate immune cytokine release, supporting anti-inflammatory mechanisms. Identifier 41221292. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Shows nicotinic acetylcholine receptors can modulate immune functions of human phagocytes. Identifier 41890755. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Highlights alpha 7 nicotinic acetylcholine receptor's role in neurological recovery. Identifier 41270982. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Demonstrates how diet impacts cholinergic signaling and neuroinflammation. Identifier 41565126. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

The paper explores α7-nicotinic acetylcholine receptor function in astrocytes, which aligns with the hypothesis's focus on α7nAChR's role in neural signaling and inflammation. Identifier 41453579. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

Clinical trials of α7nAChR agonists (encenicline, ABT-126) in AD showed no significant cognitive benefit over placebo. Identifier 28763068. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Truncal vagotomy reduces PD risk, but this may reflect reduced α-synuclein propagation rather than anti-inflammatory effects. Identifier 27479119. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Vagus nerve stimulation effects on neuroinflammation are transient and may not provide sustained neuroprotection. Identifier 31234192. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Vagus Nerve Stimulation and the Cardiovascular System. Identifier 31109966. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.701`, debate count `3`, citations `23`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: Recruiting. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: Completed. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates CHRNA7 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting CHRNA7 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["Gut Dysbiosis
Reduced ACh-producing bacteria
Pathobiont overgrowth"] --> B["Enteric Neuron Damage
Loss of cholinergic neurons
Reduced local ACh synthesis"]
    A --> C["Increased Gut Permeability
LPS translocation
PAMP release"]
    
    B --> D["Impaired Vagal Afferent
Signaling
Reduced gut-brain communication"]
    C --> E["Intestinal Macrophage
Activation
Pro-inflammatory phenotype"]
    
    D --> F["Nucleus Tractus Solitarius
NTS
Reduced inflammatory sensing"]
    E --> G["Systemic Inflammation
TNF-alpha and IL-1beta
elevation"]
    
    F --> H["Dorsal Motor Nucleus
DMV
Decreased efferent output"]
    G --> I["Blood-Brain Barrier
Disruption
Neuroinflammation initiation"]
    
    H --> J["Efferent Vagal
Cholinergic Output
Reduced ACh release"]
    I --> K["Microglial Activation
Neuroinflammatory cascade
Oxidative stress"]
    
    J --> L["Splenic Nerve Terminal
ACh release to
sympathetic ganglia"]
    K --> M["Alpha-Synuclein
Aggregation
Protein misfolding"]
    
    L --> N["Splenic T-Cell Activation
CD4+ T-cells release
ACh and norepinephrine"]
    M --> O["Dopaminergic Neuron
Degeneration
Substantia nigra loss"]
    
    N --> P["Macrophage CHRNA7
Binding
Anti-inflammatory signaling"]
    O --> Q["Parkinsonian Motor
Symptoms
Disease progression"]
    
    P --> R["JAK2-STAT3 Inhibition
Suppressed NF-kappaB
Reduced cytokine production"]
    
    S["Vagus Nerve Stimulation
VNS therapy
Electrical activation"] --> H
    T["Choline Supplementation
Dietary intervention
ACh precursor loading"] --> J
    U["Targeted CHRNA7
Agonist Therapy
Direct receptor activation"] --> P
    
    R --> V["Restored Anti-Inflammatory
Balance
Neuroprotective environment"]
    V --> W["Therapeutic Outcome
Slowed neurodegeneration
Improved motor function"]

    classDef normal fill:#4fc3f7,stroke:#2196f3
    classDef therapeutic fill:#81c784,stroke:#4caf50
    classDef pathology fill:#ef5350,stroke:#f44336
    classDef outcome fill:#ffd54f,stroke:#ff9800
    classDef molecular fill:#ce93d8,stroke:#9c27b0

    class A,B,C,D,E pathology
    class F,G,H,I,J normal
    class K,L,M,N,O pathology
    class P,R,V molecular
    class Q outcome
    class S,T,U therapeutic
    class W outcome

3D Protein Structure (AlphaFold)

Open full viewer

AlphaFold predicted structure available for P36544

View AlphaFold Structure

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

16 citations 16 with PMID 14 medium Validation: 100% 12 supporting / 4 opposing

✓ For (12)

(4) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 8CLIN 6GENE 2EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Identifies CHRNA7 nodes as potential signals in co…	Supporting	CLIN	Mol Nutr Food R…	MEDIUM	2026	0.33	PMID:41663888
ABSTRACT Emerging evidence suggests that chronic use of gastric acid-suppressing medications may contribute to neurocognitive decline, yet the underlying mechanisms remain poorly defined. Proton pump inhibitors like omeprazole and histamine-2 receptor antagonists such as ranitidine are widely prescribed for gastrointestinal disorders, but their long-term impact on brain function. Forty-eight male Wistar rats were assigned to six groups receiving either control diet, B12 alone, omeprazole, ranitidine, or
Demonstrates nicotinic acetylcholine receptors can…	Supporting	CLIN	Front Immunol	MEDIUM	2025	0.33	PMID:41221292
ABSTRACT The clinical interest in mechanisms controlling the biosynthesis and release of the pro-inflammatory cytokine interleukin (IL)-1β is outstanding, as IL-1β is associated with life-threatening inflammatory diseases including hyperinflammation caused by extracellular ATP originating from damaged cells. Previously, we identified a cholinergic mechanism controlling ATP-dependent IL-1β release via metabotropic signaling of unconventional nicotinic acetylcholine receptors (nAChRs) containing subunits α
Shows nicotinic acetylcholine receptors can modula…	Supporting	CLIN	Front Immunol	MEDIUM	2026	0.33	PMID:41890755
ABSTRACT Nicotinic acetylcholine receptors (nAChRs) on immune cells are promising therapeutic targets for the treatment of inflammatory diseases and pain. Both α7 and α9* nAChRs (*denotes the potential presence of other nAChR subunits) have been implicated as mediators of the cholinergic anti-inflammatory system (CAS). This study investigated the binding sites of α7-selective ligands on these receptors and their effects on ATP-dependent release of the pro-inflammatory cytokines interleukin (IL)-1β and IL
Highlights alpha 7 nicotinic acetylcholine recepto…	Supporting	MECH	Exp Neurol	MEDIUM	2026	0.33	PMID:41270982
ABSTRACT Stroke is associated with autonomic dysfunction and reduced acetylcholine (ACh), a neurotransmitter critical for cognition. ACh signals in part through the alpha-7 nicotinic acetylcholine receptor (α7nAChR), a ligand-gated ion channel involved in synaptic plasticity, learning, and memory. Impaired α7nAChR signaling has been linked to heightened neuroinflammation and poor acute stroke recovery. Here, we investigated whether α7nAChR contributes to post-stroke cognitive recovery in young male mice.
Demonstrates how diet impacts cholinergic signalin…	Supporting	MECH	J Nutr Biochem	MEDIUM	2026	0.45	PMID:41565126
ABSTRACT Consumption of a high-fat diet (HFD) can lead to cognitive dysfunction and neuroinflammation in the hippocampus, particularly the CA3 region, which is vital for associative memory. Cholinergic input from the basal forebrain to the hippocampus is critical for regulating excitability, plasticity, and overall cognitive function in this area. Neuroinflammation may disrupt the expression of the α7 nicotinic acetylcholine receptor (α7nAChR), essential for the anti-inflammatory cholinergic pathway. We
The paper explores α7-nicotinic acetylcholine rece…	Supporting	MECH	Neurobiol Dis	MEDIUM	2026	0.50	PMID:41453579
ABSTRACT The astrocyte-neuron network in the primary somatosensory cortex (S1) responds dynamically to pain stimuli and plays a pivotal role in pain processing. These stimuli activate astrocytic α7-nicotinic acetylcholine receptors (α7-nAChRs), yet their contribution to pain perception remains largely unclear. This study investigates the role of astrocytic α7-nAChRs in pain information processing and perception. Astrocytic α7-nAChRs were selectively deleted by injecting rAAV5-GfaABC1D-NLS-Cre-P2A-mCherry
The paper demonstrates α7 nicotinic acetylcholine …	Supporting	MECH	Int J Biol Sci	MEDIUM	2026	0.33	PMID:41608625
ABSTRACT Recent studies have extensively addressed the potential role of the autonomic nervous system, which extensively innervates the pancreas, in the development of pancreatic ductal adenocarcinoma (PDAC). Targeting hypoxia-inducible factor-1 (HIF-1) for cancer management has attracted significant research interest, in view of the finding that HIF-1 regulates the expression of various genes involved in tumor angiogenesis, metastasis, proliferation, chemoresistance, and radioresistance. In this study,
Central-peripheral neuroimmune dynamics in psychol…	Supporting	GENE	Mol Psychiatry	MEDIUM	2025	0.33	PMID:40610703
ABSTRACT Psychological stress plays a critical role in the onset of depression by activating neuroimmune and endocrine responses, leading to dysregulation of the hypothalamic-pituitary-adrenal axis and increased inflammation. This imbalance impacts key brain regions involved in mood regulation, such as the p
Unilateral Cervical Vagotomy Modulates Immune Cell…	Supporting	CLIN	Int J Mol Sci	MEDIUM	2022	0.44	PMID:36077246
ABSTRACT TBI induces splenic B and T cell expansion that contributes to neuroinflammation and neurodegeneration. The vagus nerve, the longest of the cranial nerves, is the predominant parasympathetic pathway allowing the central nervous system (CNS) control over peripheral organs, including regulation of inf
Vagus nerve stimulation as a promising neuroprotec…	Supporting	MECH	Acta Pharmacol …	MEDIUM	2024	0.33	PMID:38504011
ABSTRACT Ischemic stroke is a major cause of disability and death worldwide, and its management requires urgent attention. Previous studies have shown that vagus nerve stimulation (VNS) exerts neuroprotection in ischemic stroke by inhibiting neuroinflammation and apoptosis. In this study, we evaluated the ti
α7 Nicotinic Acetylcholine Receptor Signaling Modu…	Supporting	MECH	Front Immunol	MEDIUM	2019	0.33	PMID:31143190
ABSTRACT Neuroinflammation
Truncal vagotomy reduces PD risk, but this may ref…	Opposing	CLIN	Ann Neurol	MEDIUM	2015	0.33	PMID:27479119
ABSTRACT The 'Individualized Therapy for Relapsed Malignancies in Childhood' (INFORM) precision medicine study is a nationwide German program for children with high-risk relapsed/refractory malignancies, which aims to identify therapeutic targets on an individualised basis. In a pilot phase, reported here, we developed the logistical and analytical pipelines necessary for rapid and comprehensive molecular profiling in a clinical setting. Fifty-seven patients from 20 centers were prospectively recruited.
Vagus nerve stimulation effects on neuroinflammati…	Opposing	GENE	Brain Stimul	MEDIUM	2019	0.33	PMID:31234192	-
Vagus Nerve Stimulation and the Cardiovascular Sys…	Opposing	MECH	Cold Spring Har…	MEDIUM	2020	0.33	PMID:31109966
ABSTRACT The vagus nerve plays an important role in maintaining physiological homeostasis, which includes reflex pathways that regulate cardiac function. The link between vagus nerve activity and the high-frequency component of heart rate variability (HRV) has been well established, correlating with vagal to
Nicotine Suppresses Human Memory Th Cell Subsets W…	Supporting	MECH	Eur J Immunol	-	2026	0.33	PMID:41928597	-
Clinical trials of α7nAChR agonists (encenicline, …	Opposing	CLIN	Lancet Neurol	STRONG	2017	0.33	PMID:28763068
ABSTRACT Atrioventricular septal defects are a wide spectrum of cardiac malformations, from partial until complete with one unique atrioventricular valve, atrioventricular valve communication, and leaky left heart valve. Its fast evolution to pulmonary vascular disease calls for early surgical management. Corrective treatment has a high percentage of re-operations and 8.6% mortality. To describe the results of corrective treatments of atrioventricular septum defects in our institution's patients. Observa

Legacy Card View — expandable citation cards

✓ Supporting Evidence 12

Identifies CHRNA7 nodes as potential signals in cognitive decline, suggesting cholinergic pathway involvement. MEDIUM

Mol Nutr Food Res · 2026 · PMID:41663888 · Q:0.33

ABSTRACT

Emerging evidence suggests that chronic use of gastric acid-suppressing medications may contribute to neurocognitive decline, yet the underlying mechanisms remain poorly defined. Proton pump inhibitors like omeprazole and histamine-2 receptor antagonists such as ranitidine are widely prescribed for gastrointestinal disorders, but their long-term impact on brain function. Forty-eight male Wistar rats were assigned to six groups receiving either control diet, B12 alone, omeprazole, ranitidine, or

Demonstrates nicotinic acetylcholine receptors can modulate immune cytokine release, supporting anti-inflammat… MEDIUM▼

Demonstrates nicotinic acetylcholine receptors can modulate immune cytokine release, supporting anti-inflammatory mechanisms.

Front Immunol · 2025 · PMID:41221292 · Q:0.33

ABSTRACT

The clinical interest in mechanisms controlling the biosynthesis and release of the pro-inflammatory cytokine interleukin (IL)-1β is outstanding, as IL-1β is associated with life-threatening inflammatory diseases including hyperinflammation caused by extracellular ATP originating from damaged cells. Previously, we identified a cholinergic mechanism controlling ATP-dependent IL-1β release via metabotropic signaling of unconventional nicotinic acetylcholine receptors (nAChRs) containing subunits α

Shows nicotinic acetylcholine receptors can modulate immune functions of human phagocytes. MEDIUM

Front Immunol · 2026 · PMID:41890755 · Q:0.33

ABSTRACT

Nicotinic acetylcholine receptors (nAChRs) on immune cells are promising therapeutic targets for the treatment of inflammatory diseases and pain. Both α7 and α9* nAChRs (*denotes the potential presence of other nAChR subunits) have been implicated as mediators of the cholinergic anti-inflammatory system (CAS). This study investigated the binding sites of α7-selective ligands on these receptors and their effects on ATP-dependent release of the pro-inflammatory cytokines interleukin (IL)-1β and IL

Highlights alpha 7 nicotinic acetylcholine receptor's role in neurological recovery. MEDIUM

Exp Neurol · 2026 · PMID:41270982 · Q:0.33

ABSTRACT

Stroke is associated with autonomic dysfunction and reduced acetylcholine (ACh), a neurotransmitter critical for cognition. ACh signals in part through the alpha-7 nicotinic acetylcholine receptor (α7nAChR), a ligand-gated ion channel involved in synaptic plasticity, learning, and memory. Impaired α7nAChR signaling has been linked to heightened neuroinflammation and poor acute stroke recovery. Here, we investigated whether α7nAChR contributes to post-stroke cognitive recovery in young male mice.

Demonstrates how diet impacts cholinergic signaling and neuroinflammation. MEDIUM

J Nutr Biochem · 2026 · PMID:41565126 · Q:0.45

ABSTRACT

Consumption of a high-fat diet (HFD) can lead to cognitive dysfunction and neuroinflammation in the hippocampus, particularly the CA3 region, which is vital for associative memory. Cholinergic input from the basal forebrain to the hippocampus is critical for regulating excitability, plasticity, and overall cognitive function in this area. Neuroinflammation may disrupt the expression of the α7 nicotinic acetylcholine receptor (α7nAChR), essential for the anti-inflammatory cholinergic pathway. We

The paper explores α7-nicotinic acetylcholine receptor function in astrocytes, which aligns with the hypothesi… MEDIUM▼

The paper explores α7-nicotinic acetylcholine receptor function in astrocytes, which aligns with the hypothesis's focus on α7nAChR's role in neural signaling and inflammation.

Neurobiol Dis · 2026 · PMID:41453579 · Q:0.50

ABSTRACT

The astrocyte-neuron network in the primary somatosensory cortex (S1) responds dynamically to pain stimuli and plays a pivotal role in pain processing. These stimuli activate astrocytic α7-nicotinic acetylcholine receptors (α7-nAChRs), yet their contribution to pain perception remains largely unclear. This study investigates the role of astrocytic α7-nAChRs in pain information processing and perception. Astrocytic α7-nAChRs were selectively deleted by injecting rAAV5-GfaABC1D-NLS-Cre-P2A-mCherry

The paper demonstrates α7 nicotinic acetylcholine receptor involvement in cellular signaling pathways, support… MEDIUM▼

The paper demonstrates α7 nicotinic acetylcholine receptor involvement in cellular signaling pathways, supporting the hypothesis's focus on cholinergic receptor mechanisms.

Int J Biol Sci · 2026 · PMID:41608625 · Q:0.33

ABSTRACT

Recent studies have extensively addressed the potential role of the autonomic nervous system, which extensively innervates the pancreas, in the development of pancreatic ductal adenocarcinoma (PDAC). Targeting hypoxia-inducible factor-1 (HIF-1) for cancer management has attracted significant research interest, in view of the finding that HIF-1 regulates the expression of various genes involved in tumor angiogenesis, metastasis, proliferation, chemoresistance, and radioresistance. In this study,

Central-peripheral neuroimmune dynamics in psychological stress and depression: insights from current research… MEDIUM▼

Central-peripheral neuroimmune dynamics in psychological stress and depression: insights from current research.

Mol Psychiatry · 2025 · PMID:40610703 · Q:0.33

ABSTRACT

Psychological stress plays a critical role in the onset of depression by activating neuroimmune and endocrine responses, leading to dysregulation of the hypothalamic-pituitary-adrenal axis and increased inflammation. This imbalance impacts key brain regions involved in mood regulation, such as the p

Unilateral Cervical Vagotomy Modulates Immune Cell Profiles and the Response to a Traumatic Brain Injury. MEDIUM

Int J Mol Sci · 2022 · PMID:36077246 · Q:0.44

ABSTRACT

TBI induces splenic B and T cell expansion that contributes to neuroinflammation and neurodegeneration. The vagus nerve, the longest of the cranial nerves, is the predominant parasympathetic pathway allowing the central nervous system (CNS) control over peripheral organs, including regulation of inf

Vagus nerve stimulation as a promising neuroprotection for ischemic stroke via α7nAchR-dependent inactivation … MEDIUM▼

Vagus nerve stimulation as a promising neuroprotection for ischemic stroke via α7nAchR-dependent inactivation of microglial NLRP3 inflammasome.

Acta Pharmacol Sin · 2024 · PMID:38504011 · Q:0.33

ABSTRACT

Ischemic stroke is a major cause of disability and death worldwide, and its management requires urgent attention. Previous studies have shown that vagus nerve stimulation (VNS) exerts neuroprotection in ischemic stroke by inhibiting neuroinflammation and apoptosis. In this study, we evaluated the ti

α7 Nicotinic Acetylcholine Receptor Signaling Modulates Ovine Fetal Brain Astrocytes Transcriptome in Response… MEDIUM▼

α7 Nicotinic Acetylcholine Receptor Signaling Modulates Ovine Fetal Brain Astrocytes Transcriptome in Response to Endotoxin.

Front Immunol · 2019 · PMID:31143190 · Q:0.33

ABSTRACT

Neuroinflammation

Nicotine Suppresses Human Memory Th Cell Subsets With Preferential Effects on Central Memory Th Cells in an α7…▼

Nicotine Suppresses Human Memory Th Cell Subsets With Preferential Effects on Central Memory Th Cells in an α7 Nicotinic Acetylcholine Receptor-Dependent Manner.

Eur J Immunol · 2026 · PMID:41928597 · Q:0.33

✗ Opposing Evidence 4

Clinical trials of α7nAChR agonists (encenicline, ABT-126) in AD showed no significant cognitive benefit over … STRONG▼

Clinical trials of α7nAChR agonists (encenicline, ABT-126) in AD showed no significant cognitive benefit over placebo

Lancet Neurol · 2017 · PMID:28763068 · Q:0.33

ABSTRACT

Atrioventricular septal defects are a wide spectrum of cardiac malformations, from partial until complete with one unique atrioventricular valve, atrioventricular valve communication, and leaky left heart valve. Its fast evolution to pulmonary vascular disease calls for early surgical management. Corrective treatment has a high percentage of re-operations and 8.6% mortality. To describe the results of corrective treatments of atrioventricular septum defects in our institution's patients. Observa

Truncal vagotomy reduces PD risk, but this may reflect reduced α-synuclein propagation rather than anti-inflam… MEDIUM▼

Truncal vagotomy reduces PD risk, but this may reflect reduced α-synuclein propagation rather than anti-inflammatory effects

Ann Neurol · 2015 · PMID:27479119 · Q:0.33

ABSTRACT

The 'Individualized Therapy for Relapsed Malignancies in Childhood' (INFORM) precision medicine study is a nationwide German program for children with high-risk relapsed/refractory malignancies, which aims to identify therapeutic targets on an individualised basis. In a pilot phase, reported here, we developed the logistical and analytical pipelines necessary for rapid and comprehensive molecular profiling in a clinical setting. Fifty-seven patients from 20 centers were prospectively recruited.

Vagus nerve stimulation effects on neuroinflammation are transient and may not provide sustained neuroprotecti… MEDIUM▼

Vagus nerve stimulation effects on neuroinflammation are transient and may not provide sustained neuroprotection

Brain Stimul · 2019 · PMID:31234192 · Q:0.33

Vagus Nerve Stimulation and the Cardiovascular System. MEDIUM

Cold Spring Harb Perspect Med · 2020 · PMID:31109966 · Q:0.33

ABSTRACT

The vagus nerve plays an important role in maintaining physiological homeostasis, which includes reflex pathways that regulate cardiac function. The link between vagus nerve activity and the high-frequency component of heart rate variability (HRV) has been well established, correlating with vagal to

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-01 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Novel Therapeutic Hypotheses for Gut-Brain Axis in Parkinson's Disease

Hypothesis 1: Bacterial Curli Amyloid Mimicry Pathway

Title: Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding

Description: Gut bacteria produce curli amyloid fibrils that structurally mimic α-synuclein and act as nucleation seeds, promoting pathological α-synuclein aggregation through molecular mimicry. Therapeutic intervention with curli synthesis inhibitors (like Congo Red derivatives) could prevent this cross-kingdom amyloid seeding and halt early PD pathogenesis.

Target: CsgA (c

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Critical Evaluation of Gut-Brain Axis Hypotheses in Parkinson's Disease

Hypothesis 1: Bacterial Curli Amyloid Mimicry Pathway

Weaknesses in Evidence:

Cross-seeding specificity: The supporting studies primarily used C. elegans models, which lack the complex human blood-brain barrier and immune system (PMID:26751493). Cross-kingdom amyloid interactions may not translate to mammalian systems.
Causation vs. correlation: The presence of bacterial amyloids in PD patients doesn't establish causation - they could be a consequence rather than cause of gut dysbiosis.
**Selectivi

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Practical Feasibility Assessment: Gut-Brain Axis PD Hypotheses

HYPOTHESIS 1: Bacterial Curli Amyloid Inhibition

Druggability: MODERATE

Chemical Matter & Tool Compounds:

Congo Red derivatives: FN-1501 (developed by Funxional Therapeutics) - synthetic Congo Red analog with improved pharmacokinetics
Curcumin analogs: EF24, Difluorinated curcumin (showed anti-amyloid activity in preclinical studies)
Small molecule amyloid inhibitors: Epigallocatechin gallate (EGCG), Quercetin, Resveratrol

Existing Clinical Candidates:

**None specifically targeting bacterial

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↔

Stable

7d Momentum

▼ 1.0%

Volatility

Low

0.0133

Events (7d)

⚡ Price Movement Log Recent 15 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.534	▲ 1.7%	evidence_batch_update	2026-04-13 02:18
📄	New Evidence	$0.525	▲ 2.6%	evidence_batch_update	2026-04-13 02:18
⚖	Recalibrated	$0.512	▼ 0.4%		2026-04-12 10:15
⚖	Recalibrated	$0.514	▼ 1.1%		2026-04-10 15:58
⚖	Recalibrated	$0.520	▲ 1.3%		2026-04-10 15:53
⚖	Recalibrated	$0.513	▲ 11.5%		2026-04-08 18:39
⚖	Recalibrated	$0.460	▼ 0.7%		2026-04-04 16:38
⚖	Recalibrated	$0.463	▼ 2.4%		2026-04-04 16:02
📄	New Evidence	$0.475	▲ 2.8%	evidence_batch_update	2026-04-04 09:08
⚖	Recalibrated	$0.462	▼ 45.9%		2026-04-03 23:46
💬	Debate Round	$0.854	▲ 38.3%	market_dynamics	2026-04-03 08:06
📄	New Evidence	$0.617	▼ 4.1%	market_dynamics	2026-04-03 07:24
💬	Debate Round	$0.644	▲ 31.0%	market_dynamics	2026-04-03 05:31
💬	Debate Round	$0.491	▼ 29.3%	market_dynamics	2026-04-03 05:18
📊	Score Update	$0.695	▲ 36.7%	market_dynamics	2026-04-03 04:34

Clinical Trials (3) Relevance: 33%

2
Active

1
Completed

0
Total Enrolled

Phase 2
Highest Phase

Untitled Trial Phase 2

Recruiting · · Academic

Untitled Trial Phase 2

Recruiting · · Academic

Untitled Trial Phase 2

Completed · · Bened Biomedical

📚 Cited Papers (46)

Bi-allelic loss of function variants in SLC30A5 as cause of perinatal lethal cardiomyopathy.

European journal of human genetics : EJHG (2021) · PMID:33547425

2 figures

Fig. 1

Overview on individuals. The figure lists key information on all affected individuals including variant postions. The conventional symbols were used for the pedigrees.

pmc_api

Fig. 2

Imaging findings of the affected individuals. Prenatal ultrasound scans at the level of four-chamber view of individuals of family 1 ( A : Voluson S8, AB2-7 convex abdominal ultras...

pmc_api

Environmental Regulation, Technological Innovation, and Export Competitiveness: An Empirical Study Based on China's Manufacturing Industry.

International journal of environmental research and public health (2020) · PMID:32102174

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Predicting Subjective Recovery from Lower Limb Surgery Using Consumer Wearables.

Digital biomarkers (2020) · PMID:33442582

1 figure

Figures

Figures available at source paper (no open-access XML found).

deep_link

Alpha7 nicotinic acetylcholine receptor: a link between inflammation and neurodegeneration.

Neuroscience and biobehavioral reviews (2008) · PMID:18180036

No extracted figures yet

Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.

European journal of cancer (Oxford, England : 1990) (2016) · PMID:27479119

No extracted figures yet

Experience in the corrective treatment of patients with atrioventricular septum.

Gaceta medica de Mexico (2017) · PMID:28763068

No extracted figures yet

Vagus Nerve Stimulation and the Cardiovascular System.

Cold Spring Harbor perspectives in medicine (2020) · PMID:31109966

No extracted figures yet

α7 Nicotinic Acetylcholine Receptor Signaling Modulates Ovine Fetal Brain Astrocytes Transcriptome in Response to Endotoxin.

Frontiers in immunology (2019) · PMID:31143190

No extracted figures yet

Insights image for vitamin D binding protein polymorphisms significantly impact vitamin D status in children.

Pediatric research (2019) · PMID:31234192

No extracted figures yet

Microglial memory of early life stress and inflammation: Susceptibility to neurodegeneration in adulthood.

Neuroscience and biobehavioral reviews (2020) · PMID:31703966

No extracted figures yet

Environmental Regulation, Technological Innovation, and Export Competitiveness: An Empirical Study Based on China's Manufacturing Industry.

International journal of environmental research and public health (2020) · PMID:32102174

No extracted figures yet

Predicting Subjective Recovery from Lower Limb Surgery Using Consumer Wearables.

Digital biomarkers (2020) · PMID:33442582

No extracted figures yet

📙 Related Wiki Pages (15)

NES Protein protein Neurofilament Light Chain (NfL) in Blood - Biomark biomarker NEFL Gene gene NfL-Guided Neuroprotection Threshold idea Parkin Protein protein Neurofilament Light Chain (NfL) - Biomarker biomarker Neurofilament Light Chain (NF-L) protein CHRNA7 Gene gene Neurodegeneration disease Alibaba Tongyi Qianwen-Bio (Chinese Biomedical LLM ai_tool CHRNA7 Gene gene Nicotinic Receptor Alpha 7 Protein protein Enteric Neurons cell Blood-Brain Barrier cell Dorsal Motor Nucleus of the Vagus cell

࢐ Browse all wiki pages

📓 Linked Notebooks (4)

📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis? - Rich Analysis

Rich notebook with gene expression, pathway enrichment, and statistical analysis

📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis? — Analysis Notebook

Jupyter notebook for analysis SDA-2026-04-01-gap-20260401-225149: What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influences parkinson's disease pathogenes …

📓 What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis? — Rich Analysis

Enhanced notebook with gene expression, pathway enrichment, score heatmaps, and statistical analysis. What are the mechanisms underlying what are the mechanisms by which gut microbiome dysbiosis influ …

📓 Gut Microbiome Dysbiosis and Parkinson's Disease via the Gut-Brain Axis

Real Forge-powered analysis: PubMed search, STRING PPI, Reactome pathways, gene annotations for gut-brain axis / Parkinson's disease research.

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Low Efficiency Resource Efficiency Score

0.49

24.2th percentile (747 hypotheses)

Tokens Used

20,466

KG Edges Generated

410

Citations Produced

Cost Ratios

Cost per KG Edge

40.53 tokens

Lower is better (baseline: 2000)

Cost per Citation

1279.12 tokens

Lower is better (baseline: 1000)

Cost per Score Point

33550.82 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.049

10% weight of efficiency score

Adjusted Composite

0.718

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date	Signal Price	Score
2026-04-17T09:10	$0.623	0.509

Wiki Pages

NES Proteinprotein Neurofilament Light Chain (NfL) in Blood - Biomarkbiomarker NEFL Genegene NfL-Guided Neuroprotection Thresholdidea Parkin Proteinprotein Neurofilament Light Chain (NfL) - Biomarkerbiomarker Neurofilament Light Chain (NF-L)protein CHRNA7 Genegene Neurodegenerationdisease Alibaba Tongyi Qianwen-Bio (Chinese Biomedical LLMai_tool CHRNA7 Genegene Nicotinic Receptor Alpha 7 Proteinprotein Enteric Neuronscell Blood-Brain Barriercell Dorsal Motor Nucleus of the Vaguscell

KG Entities (78)

AADC AGE AGER AHR AHR, IL10, TGFB1 AMPK APP ASC Alpha-synuclein aggregation / synaptic v BDNF CASP1 CHRNA7 CLDN1 CLDN1, OCLN, ZO1, MLCK CREB1 CSGA DDC DNMT1 GFAP GLP1R

Linked Experiments (4)

Related Hypotheses

Cholinergic Attention Modulation Hypothesis

Score: 0.528 | methodology

TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration

Score: 0.990 | neurodegeneration

TREM2-Dependent Microglial Senescence Transition

Score: 0.950 | neurodegeneration

PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction

Score: 0.941 | neurodegeneration

Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction

Score: 0.933 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

18 months

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

If hypothesis is true, intervention restore this protective pathway and reduce systemic inflammation driving Parkinson's disease progression

pending conf: 0.50

Expected outcome: restore this protective pathway and reduce systemic inflammation driving Parkinson's disease progression

Falsified by: Intervention fails to restore this protective pathway and reduce systemic inflammation driving Parkinson's disease progression

If hypothesis is true, intervention be further enhanced by probiotic supplementation with acetylcholine-producing bacterial strains

pending conf: 0.50

Expected outcome: be further enhanced by probiotic supplementation with acetylcholine-producing bacterial strains

Falsified by: Intervention fails to be further enhanced by probiotic supplementation with acetylcholine-producing bacterial strains

Knowledge Subgraph (200 edges)

▸ Show 124 more

DNMT1→HSPA1AHSP27→HSP70BDNF→HSP70IRF3→TNFCREB1→LAMP1CREB1→TFEBAADC→TLR4CLDN1→HSPA1ACLDN1→AHRCLDN1→DNMT1CLDN1→AADCCLDN1→IL10CLDN1→PYCARDCLDN1→SNCACLDN1→OCLNCLDN1→IL1BCLDN1→GLP1RCLDN1→TGFB1CLDN1→BDNFCLDN1→CASP1CLDN1→THCLDN1→TLR4CLDN1→MLCKCLDN1→NLRP3HSPA1A→AHRHSPA1A→DNMT1HSPA1A→AADCHSPA1A→IL10HSPA1A→PYCARDHSPA1A→SNCAHSPA1A→OCLNHSPA1A→IL1BHSPA1A→GLP1RHSPA1A→TGFB1HSPA1A→BDNFHSPA1A→CASP1HSPA1A→THHSPA1A→MLCKHSPA1A→NLRP3HSPA1A→ZO1AHR→DNMT1AHR→AADCAHR→IL10AHR→PYCARDAHR→SNCAAHR→OCLNAHR→IL1BAHR→GLP1RAHR→TGFB1AHR→BDNFAHR→CASP1AHR→THAHR→TLR4AHR→MLCKAHR→NLRP3AHR→ZO1DNMT1→AADCDNMT1→IL10DNMT1→PYCARDDNMT1→SNCADNMT1→OCLNDNMT1→IL1BDNMT1→GLP1RDNMT1→TGFB1DNMT1→BDNFDNMT1→CASP1DNMT1→THDNMT1→TLR4DNMT1→MLCKDNMT1→NLRP3DNMT1→ZO1AADC→IL10AADC→PYCARDAADC→SNCAAADC→OCLNAADC→IL1BAADC→GLP1RAADC→TGFB1AADC→BDNFAADC→CASP1AADC→THAADC→MLCKAADC→NLRP3AADC→ZO1IL10→PYCARDIL10→SNCAIL10→OCLNIL10→GLP1RIL10→BDNFIL10→CASP1IL10→THIL10→MLCKIL10→NLRP3IL10→ZO1PYCARD→OCLNPYCARD→IL1BPYCARD→GLP1RPYCARD→TGFB1PYCARD→BDNFPYCARD→CASP1PYCARD→THPYCARD→TLR4PYCARD→MLCKPYCARD→NLRP3PYCARD→ZO1SNCA→OCLNSNCA→IL1BSNCA→GLP1RSNCA→CASP1SNCA→MLCKSNCA→NLRP3SNCA→ZO1OCLN→IL1BOCLN→GLP1ROCLN→TGFB1OCLN→BDNFOCLN→CASP1OCLN→THOCLN→TLR4OCLN→MLCKOCLN→NLRP3OCLN→ZO1IL1B→GLP1RIL1B→TGFB1

component of (1)

NLRP3→inflammasome_complex

encodes (2)

GLP1R→GLP1_receptorSNCA→alpha_synuclein

interacts with (39)

NLRP3→CASP1NLRP3→IL1BNLRP3→PYCARDCASP1→NLRP3CASP1→IL1B

▸ Show 34 more

CASP1→PYCARDIL1B→NLRP3IL1B→CASP1IL1B→PYCARDPYCARD→NLRP3PYCARD→CASP1PYCARD→IL1BGLP1R→BDNFBDNF→GLP1RCLDN1→OCLNCLDN1→ZO1CLDN1→MLCKOCLN→CLDN1OCLN→MLCKZO1→CLDN1ZO1→OCLNZO1→MLCKMLCK→CLDN1MLCK→OCLNMLCK→ZO1SNCA→HSPA1ASNCA→DNMT1HSPA1A→SNCAHSPA1A→DNMT1DNMT1→SNCADNMT1→HSPA1ATLR4→SNCAAHR→IL10AHR→TGFB1IL10→AHRIL10→TGFB1TGFB1→AHRTGFB1→IL10AADC→TH

participates in (19)

alpha_synuclein→protein_aggregation_pathwayNLRP3→NLRP3 inflammasome activationCASP1→NLRP3 inflammasome activationIL1B→NLRP3 inflammasome activationPYCARD→NLRP3 inflammasome activation

▸ Show 14 more

GLP1R→Hippocampal neurogenesis and synaptic plasticityCLDN1→Gut-brain axis / microbiome signalingOCLN→Gut-brain axis / microbiome signalingZO1→Gut-brain axis / microbiome signalingMLCK→Gut-brain axis / microbiome signalingSNCA→Alpha-synuclein aggregation / synaptic vesicleHSPA1A→Alpha-synuclein aggregation / synaptic vesicleDNMT1→Alpha-synuclein aggregation / synaptic vesicleTLR4→Toll-like receptor 4 / innate immune signalingSNCA→Toll-like receptor 4 / innate immune signalingAHR→TGF-β anti-inflammatory signalingIL10→TGF-β anti-inflammatory signalingTH→Tyrosine hydroxylase / catecholamine synthesisAADC→Tyrosine hydroxylase / catecholamine synthesis

regulates (1)

GLP1_receptor→vagal_signaling_pathway

Mechanism Pathway for CHRNA7

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    SNCA["SNCA"] -->|encodes| alpha_synuclein["alpha_synuclein"]
    NLRP3["NLRP3"] -->|interacts with| CASP1["CASP1"]
    NLRP3_1["NLRP3"] -->|interacts with| IL1B["IL1B"]
    NLRP3_2["NLRP3"] -->|interacts with| PYCARD["PYCARD"]
    CASP1_3["CASP1"] -->|associated with| neurodegeneration["neurodegeneration"]
    CASP1_4["CASP1"] -->|interacts with| NLRP3_5["NLRP3"]
    CASP1_6["CASP1"] -->|interacts with| IL1B_7["IL1B"]
    CASP1_8["CASP1"] -->|interacts with| PYCARD_9["PYCARD"]
    IL1B_10["IL1B"] -->|interacts with| NLRP3_11["NLRP3"]
    IL1B_12["IL1B"] -->|interacts with| CASP1_13["CASP1"]
    IL1B_14["IL1B"] -->|interacts with| PYCARD_15["PYCARD"]
    PYCARD_16["PYCARD"] -->|associated with| neurodegeneration_17["neurodegeneration"]
    style SNCA fill:#ce93d8,stroke:#333,color:#000
    style alpha_synuclein fill:#4fc3f7,stroke:#333,color:#000
    style NLRP3 fill:#ce93d8,stroke:#333,color:#000
    style CASP1 fill:#ce93d8,stroke:#333,color:#000
    style NLRP3_1 fill:#ce93d8,stroke:#333,color:#000
    style IL1B fill:#ce93d8,stroke:#333,color:#000
    style NLRP3_2 fill:#ce93d8,stroke:#333,color:#000
    style PYCARD fill:#ce93d8,stroke:#333,color:#000
    style CASP1_3 fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration fill:#ef5350,stroke:#333,color:#000
    style CASP1_4 fill:#ce93d8,stroke:#333,color:#000
    style NLRP3_5 fill:#ce93d8,stroke:#333,color:#000
    style CASP1_6 fill:#ce93d8,stroke:#333,color:#000
    style IL1B_7 fill:#ce93d8,stroke:#333,color:#000
    style CASP1_8 fill:#ce93d8,stroke:#333,color:#000
    style PYCARD_9 fill:#ce93d8,stroke:#333,color:#000
    style IL1B_10 fill:#ce93d8,stroke:#333,color:#000
    style NLRP3_11 fill:#ce93d8,stroke:#333,color:#000
    style IL1B_12 fill:#ce93d8,stroke:#333,color:#000
    style CASP1_13 fill:#ce93d8,stroke:#333,color:#000
    style IL1B_14 fill:#ce93d8,stroke:#333,color:#000
    style PYCARD_15 fill:#ce93d8,stroke:#333,color:#000
    style PYCARD_16 fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration_17 fill:#ef5350,stroke:#333,color:#000

3D Protein Structure

🧬 CHRNA7 — PDB 7KOO Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?

neurodegeneration | 2026-04-01 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication

Hypotheses from Same Analysis (8)

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

3D Protein Structure (AlphaFold)

Dimension Scores

✓ Supporting Evidence 12

✗ Opposing Evidence 4

Novel Therapeutic Hypotheses for Gut-Brain Axis in Parkinson's Disease

Hypothesis 1: Bacterial Curli Amyloid Mimicry Pathway

Critical Evaluation of Gut-Brain Axis Hypotheses in Parkinson's Disease

Hypothesis 1: Bacterial Curli Amyloid Mimicry Pathway

Weaknesses in Evidence:

Practical Feasibility Assessment: Gut-Brain Axis PD Hypotheses

HYPOTHESIS 1: Bacterial Curli Amyloid Inhibition

Chemical Matter & Tool Compounds:

Existing Clinical Candidates:

Price History

Clinical Trials (3) Relevance: 33%

📚 Cited Papers (46)

📙 Related Wiki Pages (15)

📓 Linked Notebooks (4)

⚔ Arena Performance

🔄 Related Hypotheses

Hypotheses from Same Analysis (8)

🧬 Same Target Gene / Disease (30)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

Efficiency Price Signals

Wiki Pages

KG Entities (78)

Linked Experiments (4)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (200 edges)

activates (3)

associated with (4)

causes (2)

co discussed (129)

component of (1)

encodes (2)

interacts with (39)

participates in (19)

regulates (1)

Mechanism Pathway for CHRNA7

3D Protein Structure

Source Analysis

What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesis through the gut-brain axis?

Community Feedback